Rituximab therapy improves recalcitrant Pemphigus vulgaris by Noormohammadpour, Pedram et al.
EXCLI Journal 2015;14:109-116– ISSN 1611-2156 
Received: September 19, 2014, accepted: November 02, 2014, published: January 21, 2015 
 
 
109 
Original article: 
RITUXIMAB THERAPY IMPROVES RECALCITRANT  
PEMPHIGUS VULGARIS 
 
Pedram Noormohammadpour1,2, Amirhooshang Ehsani1, Hossein Mortazavi1,  
Maryam Daneshpazhooh1, Kamran Balighi1, Mohammad Mofidi1,*, Fatemeh Gholamali1,  
Ali Sadeghinia1 
 
1 Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences,  
Tehran, Iran 
2 Bullous Research Center, Tehran University of Medical Sciences, Tehran, Iran 
 
* Corresponding author: Mohammad Mofidi, Razi Hospital, Vahdat-e-eslami Square, 
Vahdat-e-eslami Street, Tehran, Iran, Postal code: 11996-63911, Tel: +98 21 5563 3728; 
E-mail: doctormofidi@yahoo.com  
 
http://dx.doi.org/10.17179/excli2014-603 
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/). 
 
ABSTRACT 
Pemphigus is a severe life-threatening blistering disease associated with autoantibodies against cell adhesion 
proteins desmogleins 1 and 3. Patients with severe pemphigus commonly show high rates of relapse after con-
ventional immunosuppressive therapy. The newly developed drug Rituximab showed impressing promises in the 
treatment of refractory pemphigus vulgaris (PV). In the present study the efficacy of a single course rituximab 
therapy in the treatment of PV was investigated. Eighteen patients with severe recalcitrant PV were recruited to 
this study. Pemphigus disease activity index (PDAI), anti-desmoglein 1 and anti-desmoglein 3 antibody titers, 
and percent of CD20 positive cells were measured at baseline, 10 ± 1, and 22 ± 2 weeks after rituximab therapy. 
Rituximab was given intravenously at dose 375 mg/m2 once weekly for 4 weeks. Rituximab therapy caused a 
dramatic reduction in the PDAI, accompanied by decreases in anti-desmoglein 1 and anti-desmoglein 3 antibody 
titers over the follow-up course. The B-cell population decreased at the first follow-up, but returned to its base-
line levels at the second follow-up. Rituximab therapy decreased the dose of immunosuppressive drugs required 
to control the disease. It seems that the rituximab may be effective and safe for treatment of refractory PV. 
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INTRODUCTION  
Pemphigus is a severe, potentially life-
threatening autoimmune disease associated 
with mucous and cutaneous blisters caused 
by autoantibodies against cell adhesion pro-
teins desmogleins 1 (Dsg1) and 3 (Dsg3). 
There are two major types of the disease. In 
pemphigus foliaceus, superficially occurring 
blisters are typically associated with autoan-
tibodies to the Dsg1, whereas in the more 
severe pemphigus vulgaris (PV), which is 
characterized by deeper blisters in the su-
prabasal layer of the epidermis, IgG antibod-
ies to both the Dsg1 and Dsg3 implicate in 
pathogenesis of the disease. Binding of anti-
bodies to the desmosomal proteins gives rise 
to impaired cell-cell adhesion between 
neighboring keratinocytes and subsequent 
blister formation (Grando, 2012; Scully and 
Challacombe, 2002; Waschke, 2008).  
Conventionally, the pemphigus has been 
treated with corticosteroids and immunosup-
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pressants to decrease antibody production by 
generally suppressing the immune system. 
Although the use of these agents dramatical-
ly improved the prognosis of the disease, but 
it also raised the morbidity associated with 
the long-term use of these drugs, including 
fatal infection and secondary cancers. This 
has prompted the development of alternative 
therapies including the biological agents 
such as intravenous immunoglobulin and 
rituximab, as well as interventional treat-
ments such as plasmapheresis and immuno-
adsorption (Ruocco et al., 2013).  
Rituximab is a potent mouse/human chi-
meric anti-CD20 monoclonal antibody that 
selectively targets and depletes antibody-
producing B lymphocytes, but spares long-
lived plasma cells that are resident in the 
bone marrow and represent the major source 
of serum antibodies. Consequently, rituxi-
mab induces a decline of circulating anti-
desmoglein autoantibodies. Additionally, it 
leads to a decrease in desmoglein-specific 
auto-reactive T cells. Therefore, rituximab 
has been reported to be beneficial in treating 
PV (Bomm et al., 2013; El Tal et al., 2006; 
Zambruno and Borradori, 2008).  
In order to further explore the efficacy of 
rituximab therapy in PV patients, we con-
ducted a prospective study in which the ef-
fect of rituximab administration on the clini-
cal outcome, Dsg1 and Dsg3 antibody titers, 
and percent of CD20 positive cells was as-
sessed in a group of PV patients in Iran. 
Considering the extremely high price of 
rituximab (Marzano et al. , 2007), making a 
medical decision on prescribing the therapy 
requires a satisfactory level of optimism to-
ward its clinical efficacy, assuring a pro-
longed, safe, and cost-effective outcome. 
Here we report promising results of our 
study, which together with those previously 
reported, may help dermatologists to make a 
better decision on the approaches for manag-
ing severe corticosteroid- and immunosup-
pressive-refractory PV. 
	
METHODS 
This prospective study was conducted at 
the Razi Hospital, Tehran, Iran from 2012 to 
2013. The study protocol was approved by 
the ethics committee of Tehran University of 
Medical Sciences. Patients with severe re-
fractory PV were enrolled in the study. The 
diagnosis of PV was made on the basis of 
typical clinical presentation and laboratory 
evaluations, including histological and im-
munological criteria (Harman et al., 2003). 
The refractoriness of the disease was defined 
as recurrent blister formation despite immu-
nosuppressive therapy with prednisolone 
>10 mg daily and/or immunosuppressants 
(Azathioprine 2 mg/kg daily or equivalent 
immunosuppression) (Marzano et al., 2007). 
Written informed consents were obtained 
from all participants. All study patients had a 
clear indication for rituximab treatment, and 
none of them had a severe cardiac disease, 
hepatic or renal disorder, active infection, 
immunodeficiency, or cancer.  
Basic demographic information on the 
patients’ age and gender was collected. The 
baseline clinical status of pemphigus, de-
fined as pemphigus disease activity index 
(PDAI) (Grover, 2011; Murrell et al., 2008) 
previously proved to be the most valid scor-
ing system in the assessment of pemphigus 
(Rahbar et al., 2014), and the dosage of the 
prescribed corticosteroid and immunosup-
pressants were recorded. Anti-Dsg1 and anti-
Dsg3 autoantibodies were titered by enzyme-
linked immunosorbent assay [EUROIM-
MUN, Germany]. Percent of CD20 positive 
blood cells was measured using flow cyto-
metry [kit: Daco, Denmark; device: Partec 
PAS, Germany]. Then, all patients were 
treated with intravenous rituximab 375 mg/ 
m2 body surface once weekly for 4 consecu-
tive weeks. The severity of pemphigus, the 
dosage of corticosteroid and/or immunosup-
pressants, the anti-Dsg1 and anti-Dsg3 anti-
body titers, and the percent of CD20 express-
ing cells were evaluated, on average, 10 (± 
SEM: 1) and 22 (± 2) weeks following the 
rituximab therapy. The dosage of cortico-
steroid was tapered by approximately 30 % 
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when a minimum reduction of 30 % was ob-
served in the PDAI score relative to the pre-
vious evaluation. Only patients who were 
accessed for both of the follow-up assess-
ments were ultimately included in the data 
analysis.  
Data were analyzed using IBM SPSS sta-
tistics 20. The normal distribution of data 
was assessed using the Shapiro-Wilk W test. 
Since the distributions of anti-Dsg1 and anti-
Dsg3 antibody titers and CD20 positive frac-
tion violated the normal fitting, non-
parametric tests were used for subsequent 
data analysis. Friedman’s test was applied to 
explore overall significant differences in the 
PDAI, anti-Dsg1 and anti-Dsg3 antibody ti-
ters, and percent of CD20 positive cells over 
the three evaluation occasions. To examine 
where the differences actually occurred, sep-
arate Wilcoxon signed-rank tests were ap-
plied to the different combinations of related 
groups. The Spearman rho test was utilized 
to explore associations between the PDAI 
and anti-Dsg1, anti-Dsg3, and CD20 positive 
fraction. Data are presented as median (in-
terquartile range). Two-tailed p values less 
than 0.05 were considered significant. 
 
RESULTS 
A total of 24 patients with recalcitrant 
PV were enrolled in the study and treated 
with rituximab, from which 18 patients (13 
men and 5 women) attended both of the fol-
low-up sessions and included in the final 
analysis. Among these patients, 5 had muco-
sal and 13 had mucocutaneous PV. The me-
dian (interquartile range) age of the patients 
was 33.5 (26‒46.5) years. At the outset of 
the study, all of the patients were on predni-
solone therapy 20‒90 mg daily, and 9 of 
them were concurrently receiving immuno-
suppressants (2 patients: mycophenolate mo-
fetil 2 g daily; 4 patients: azathioprine 100 
mg daily; and 3 patients: methotrexate 
7.5‒10 mg weekly). The baseline and post-
rituximab PDAI score, anti-Dsg1 and anti-
Dsg3 antibody titers, and CD20 positive 
cells fraction are presented in Table 1.  
The PDAI showed a significant decrease 
over the rituximab treatment and follow-up 
course [Friedman’s test: Χ2 (2) = 32.44, p < 
0.001]. Wilcoxon signed ranks tests revealed 
that the differences occurred at both the first 
(Z = -3.73, p < 0.001) and the second follow-
up evaluations (Z = -3.72, p < 0.001 com-
pared with the baseline; Z = -2.37, p = 0.02 
compared with the first follow-up) subse-
quent to rituximab therapy. All cases showed 
a dramatic decrease in their PDAI at the first 
follow-up, and except for 2 cases, all of the 
patients had a lower PDAI at the second fol-
low-up relative to the first one. 
 
 
Table 1: Baseline and post-rituximab status of PDAI, anti-Dsg1 and anti-Dsg3 antibody titers, and 
CD20 positive cells fraction 
 
PDAI Anti-Dsg1 (U/ml) Anti-Dsg3 (U/ml) CD20+ fraction (%) 
Before rituximab  
therapy 
80 (51.75‒103) 117 (7.15‒293) 122 (30.5‒218.75) 1.85 (1.07‒6.55) 
First follow-up  
(~10 weeks) after  
rituximab therapy  39.5 (25.25‒63)*** 11.5 (2.9‒89)** 44.5 (10‒71.25)** 0.75 (0.60‒1.45) * 
Second follow-up  
(~22 weeks) after  
rituximab therapy 20.5 (11.5‒30)*** † 6.05 (2.15‒111.25) 38.5 (5.55‒134)* 1.45 (1.07‒2.17) † 
Data are presented as median (interquartile range). PDAI, pemphigus disease activity index. * P < 0.05, ** P < 0.01, *** P < 
0.001 relative to the baseline; † P < 0.05 relative to the first follow-up 
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There was a significant overall change in 
anti-Dsg1 antibody titer over the treatment 
and follow-up course [Friedman’s test: Χ2 (2) 
= 12.19, p = 0.002]. Pairwise comparisons 
revealed that the antibody titer decreased 
significantly 10 weeks after the rituximab 
treatment relative to the baseline levels (Z =  
-3.33, p = 0.001), but there was no signifi-
cant change occurred at the second follow-up 
occasion (Z = -1.76, p = 0.07 compared with 
the baseline; Z = -0.16, p = 0.86 compared 
with the first follow-up). Moreover, an over-
all significant difference was found in the 
anti-Dsg3 antibody titer over the treatment 
and follow-up period [Friedman’s test: Χ2 (2) 
= 11.74, p = 0.003]. Post hoc analysis with 
Wilcoxon test showed that the anti-Dsg3 an-
tibody decreased after the rituximab treat-
ment (Z = -3.10, p = 0.002) but remained 
stable over the later follow-up course (Z =  
-2.41, p = 0.01 compared with the baseline; 
Z = -0.41, p = 0.68 compared with the first 
follow-up). Rituximab therapy decreased the 
number of patients with positive levels of 
anti-Dsg1 and anti-Dsg3 antibodies (Figure 
1). 
The proportion of CD20 positive cells 
exhibited a significant decrease over the 
treatment and follow-up period [Friedman’s 
test: Χ2 (2) = 12.02, p = 0.002]. Further anal-
ysis showed that the percent of CD20 posi-
tive cells decreased after rituximab therapy 
(Z = -2.37, p = 0.02) but started to increase 
again at the second follow-up (Z = -1.89, p = 
0.06 compared with the baseline; Z = 2.00, 
p = 0.04 compared with the first follow-up).  
Analysis of the data with Spearman rho 
test showed that the PDAI was significantly 
correlated with anti-Dsg1 and anti-Dsg3 ti-
ters on almost all measurements, but not with 
the CD20 positive cell fraction (Table 2).  
The median doses of prednisolone before 
rituximab administration and at the two fol-
low-up occasions were as follows, respec-
tively: 40 (35‒62.5), 30 (20‒32.5), and 18.75 
(16.87‒25.62) mg/day. Statistical analysis 
showed that the required dose of corticoster-
oid therapy to control the adverse effects of 
pemphigus declined significantly following 
the rituximab therapy [Friedman’s test: Χ2 
(2) = 32.11, p < 0.001]. Pairwise compari-
sons revealed that the need for corticosteroid 
administration was decreased at the both fol-
low-up sessions (first follow-up: Z = -3.63, 
p < 0.001; second follow-up: Z = -3.73, 
p < 0.001 compared with the baseline; Z =  
-2.99, p = 0.003 compared with the first fol-
low-up). However, at the end of the study, 
the dose of immunosuppressants was de-
creased in 4, remained fixed in 3, and in-
creased in 2 patients. Additionally, one pa-
tient started to receive mycophenolate mo-
fetil.  
 
 
Figure 1: Scatterplot showing the number of pa-
tients with negative (‒), intermediate (×), and 
positive (+) anti-Dsg1 (A) and anti-Dsg3 (B) anti-
body titers over the rituximab treatment and fol-
low-up course. Apparently, rituximab therapy 
decreased the number of patients with positive 
anti-Dsg1 and anti-Dsg3 titers. The gridlines re-
present the lower and upper limits of negative, 
intermediate, and positive titers. 
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Table 2: Correlation between the PDAI and anti-Dsg1, anti-Dsg3, and CD20 positive cells 
   Anti-Dsg1 (U/ml) Anti-Dsg3 (U/ml) CD20+ fraction 
PDAI Baseline  CC 
p value 
0.63 
0.005** 
0.51 
0.03* 
‒0.11 
0.66 
First follow-up CC 
p value 
0.66 
0.003** 
0.39 
0.11 
‒0.36 
0.14 
Second follow-up CC 
p value 
0.63 
0.005** 
0.55 
0.02* 
0.14 
0.58 
CC, correlation coefficient (Spearman rho); PDAI, pemphigus disease activity index; * and ** represent significant correlations at 
0.05 and 0.01 levels, respectively 
 
 
 
DISCUSSION 
The main finding of this study was that 
rituximab treatment improved severe refrac-
tory PV, as demonstrated with decreases in 
the PDAI, anti-Dsg1 and anti-Dsg3 antibody 
titers, percent of CD20 positive cells, and 
required corticosteroid dose to control the 
disease.  
Several lines of evidence indicated that 
rituximab therapy may be promising for im-
proving severe refractory PV. In this regard, 
Arin et al. reported that a single course ritux-
imab treatment elicited clinical improvement 
in 5 patients with refractory pemphigus over 
a follow-up period of up to 3 years, allowing 
immunosuppressive treatment to be reduced 
or terminated (Arin et al., 2005). Moreover, 
Pfütze et al. reported that rituximab therapy 
in 5 patients with mucosal PV induced excel-
lent clinical responses which were associated 
with a significant reduction in prednisolone 
dosage and a decrease in anti-Dsg-specific 
IgG. The patients had no or only minimal 
residual symptoms over a 12-month period 
after the therapy (Pfütze et al., 2009). Joly et 
al. reported that from 21 patients with recal-
citrant PV, who were treated with 4 weekly 
infusions of 375 mg of rituximab per square 
meter of body-surface area, 19 patients dis-
played complete remission of the disease at 3 
months (Joly et al., 2007). Furthermore, 
Cianchini et al. reported that treatment with 
the same regimen of rituximab in patients 
with refractory PV and pemphigus foliaceus 
resulted in a good clinical response during an 
18-month follow-up period, along with a 
consensual decline of the serum an-
tidesmoglein titers (Cianchini et al., 2007). 
Additionally, it has been shown that patients 
treated with rituximab earlier in the disease 
course may have better outcomes, enduring 
complete remission with no or minimal sys-
temic therapy for 19 months (Lunardon et 
al., 2012). Other studies also indicated that 
adjuvant rituximab therapy may hold prom-
ises in long-lasting treatment of severe recal-
citrant PV with no or slight adverse drug-
related events (Baum et al., 2013; Behzad et 
al., 2012; Cho et al., 2014; Corral et al., 
2013; Craythorne et al., 2011; El Tal et al., 
2006; Eming et al., 2008). 
In line with the previous studies, we have 
shown that a single cycle rituximab therapy 
together with conventional immunosuppres-
sive treatment resulted in remarkable clinical 
improvements in patients with severe corti-
costeroid- and immunosuppressant-recalci-
trant PV. The clinical improvement was ac-
companied by a decrease in anti-Dsg1 and 
anti-Dsg3 titers, as demonstrated by a signif-
icant association between the PDAI and an-
tibodies against the Dsg1 and Dsg3, which 
suggests that these autoantibodies implicate 
in pathogenesis of the pemphigus. However, 
anti-Dsg1 and anti-Dsg3 titers remained pos-
itive in 36 and 64 percent of the patients, re-
spectively. This is in agreement with other 
studies showing decreases in the anti-Dsg1 
and anti-Dsg3 antibodies subsequent to 
rituximab therapy (Muller et al., 2010; 
Pfütze et al., 2009; Reguiai et al., 2012), but 
still positive titers in most of the patients 
(Reguiai et al., 2012). The persistence of cir-
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culating anti-Dsg1 and anti-Dsg3 autoanti-
bodies during the remission of PV is still not 
fully understood. It might be explained by 
the expression of nonpathogenic epitopes on 
the Dsg1 and Dsg3 ectodomains, causing 
defective interaction with the fatty acid sig-
naling complex ligand strongly implicated in 
acantholysis development (Amagai et al., 
2006). 
What is more, after an initial remarkable 
decline, anti-Dsg1 and anti-Dsg3 antibodies 
followed seemingly different time courses, 
as the former began to return to its baseline 
value approximately 22 weeks after rituxi-
mab therapy, while the latter continued to 
dwindle over time. Indeed, anti-Dsg1 also 
exhibited a decrease at the second follow-up, 
but it did not reach significance only with a 
trivial shortcoming (p = 0.07), mainly be-
cause of some increases occurred in 6 out of 
18 patients. Nevertheless, parts of B-cell 
population might have been preferentially 
affected by rituximab. It has been shown that 
at least five to six different B-cell clones 
may be involved in producing pathogenic 
anti-Dsg3 antibodies and rituximab may 
have different effects on these clones. As a 
result, some of these clones may shutdown 
later than others and continue to produce 
some anti-Dsg3 antibodies for a while 
(Hammers et al., 2014). This may describe 
different response of anti-Dsg1 and anti-
Dsg3 antibodies to treatment with this drug. 
Moreover, rituximab was found to selective-
ly reduce anti-Dsg1 and anti-Dsg3 antibodies 
while causing significant increases in anti-
VZV and anti-EBV antibodies through dif-
ferent effects on B-cell activating factor 
(BAF) and a proliferation inducing ligand 
(APRIL) (Nagel et al., 2009). This may fur-
ther elucidate possible diverse effects of 
rituximab on different cell population and 
even on different B-cell clones. 
Percent of CD20 positive cells was not 
connected with the disease activity, even 
though the CD20 fraction showed significant 
reductions on the first follow-up after the 
rituximab therapy relative to the baseline 
levels. This may imply that the rituximab 
effect is not mediated only via B-cell deple-
tion (Zambruno and Borradori, 2008). What 
is more, CD20 fraction returned to the base-
line levels at the second follow-up (22 weeks 
after rituximab therapy), indicating repopula-
tion of B-lymphocytes in the presence of 
clinical remission. However, Mouquet et al. 
showed that the B-cell population depleted 
days after rituximab therapy, remained in 
complete depletion for 6 months, started to 
reconstitute between month 6 and 9, and 
never reached to the baseline levels until 2 
years (Mouquet et al., 2008). The reason for 
this discrepancy is not clear to us. However, 
it might be due to the different way of moni-
toring B-lymphocytes, in that, they measured 
CD19+ B-cells, whereas in our study we 
measured CD20+ B-cells. It should be noted 
that assessment of CD20 by flow cytometry 
may be impaired in the presence of rituxi-
mab in the plasma (Arin et al., 2005). 
Regarding the dosage of rituximab thera-
py, we used a regimen previously applied in 
other studies, namely 375 mg/m2 body sur-
face once weekly for four consecutive weeks 
(El Tal et al., 2006; Feldman et al., 2012; 
Marzano et al., 2007; Muller et al., 2010; 
Pfütze et al., 2009; Reguiai et al., 2012). 
This regimen appears to be effective in ap-
proximately all of these studies. In our study, 
all of the patients treated with this dose 
showed excellent clinical improvements. On-
ly 2 patients showed partial increases in their 
disease activity at the second follow-up 
compared to the first evaluation. Consistent 
with this, it has been shown that pemphigus 
patients treated with 3 or more infusions of 
rituximab at dose 375 mg/m2 demonstrated 
better outcomes in time to complete remis-
sion and relapse rate relative to those treated 
with 2 infusions of rituximab at the same 
dose (Kim et al., 2011). Additionally, in a 
previous study performed in our department, 
the same regimen was used for treating 40 
PV patients, all of which showed an initial 
clinical improvement 6.35 weeks following 
the rituximab treatment and a marked clini-
cal improvement after a mean of 10.13 
months (Balighi et al., 2013). However, a 
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fixed-dose rheumatoid arthritis regimen of 
rituximab (1 g intravenously on days 1 and 
15, followed by 500 mg intravenously if 
clinically warranted at 6-month intervals or 
repeated full dosing) was recently proved to 
be efficacious and well tolerated in patients 
with PV, and proposed for administration in 
patients who do not achieve remission after 
one cycle or patients who experience relapse 
(Heelan et al., 2014). Side effects of rituxi-
mab include systemic infections, deep ve-
nous thrombosis, long-term reductions in the 
plasma levels of gammaglobulin, and neu-
tropenia (Ruocco et al., 2013). None of the 
patients in our study exhibited these adverse 
effects, which implies the safety of the 
treatment protocol.  
One limitation of this study was the lack 
of a control group of patients with no rituxi-
mab therapy due to ethical considerations. 
However, it should be reminded that the pa-
tients recruited to this study were non-
responder to conventional immunosuppres-
sive-based treatment regimens, which obvi-
ated the need for including control subjects. 
An imaginable solution to this drawback 
could be assessing retrospectively the data 
from patients with recalcitrant PV disease 
but with no alternative treatment. Indeed, 
one study followed up clinically and immu-
nologically severe PV patients treated with 
or without rituximab (Reguiai et al., 2012). 
However, it failed to find out any significant 
superiority for rituximab therapy over the 
immunosuppressive alone therapy in terms 
of long-term remission rate and immunolog-
ic profile of anti-Dsg1 and anti-Dsg3 titers.   
In conclusion, this study highlights the 
prolonged effect and disease control after 
one single course of rituximab therapy. The 
clinical improvement was associated with 
decreases in the doses of corticosteroids and 
immunosuppressants, and accompanied with 
reductions in anti-Dsg1 and anti-Dsg3 anti-
bodies. Percent of CD20 positive cells de-
clined at the first follow-up, but recovered 
later at the second follow-up. No adverse 
effect related to the rituximab was observed 
among the study patients. Taken together, it 
seems that rituximab may be effective and 
safe for treatment of refractory PV. 
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